Form 4: Director Zhang Mao Acquires Stock Options in Harvard Apparatus Regenerative Technology

Director Zhang Mao acquired stock options in Harvard Apparatus Regenerative Technology, Inc. on September 3, 2024, as part of an annual equity grant.

Summary

• On September 3, 2024, Zhang Mao, a director of Harvard Apparatus Regenerative Technology, Inc. (HRGN), acquired 7,198 stock options.
• The options were granted as part of the annual equity grant for non-employee directors.
• The exercise price of the options is $4.12.
• The options expire on September 3, 2034.
• The options vest in four equal installments on December 3, 2024, March 3, 2025, June 3, 2025, and September 3, 2025.

Sentiment

Score: 6

Explanation: The document is a standard SEC Form 4 filing, indicating a routine stock option grant to a director. It doesn't contain any particularly positive or negative information, hence a neutral sentiment score.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages continued service on the board.

Industry Context

Stock option grants to directors are a common practice in publicly traded companies to incentivize and align their interests with shareholders.

Comparison to Industry Standards

• Stock option grants to non-employee directors are a standard form of compensation in many publicly traded companies.
• The vesting schedule of four equal installments over a year is also a common practice.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of the shareholders, potentially leading to better corporate governance and decision-making.

Key Dates